Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Invivyd Inc.

Healthcare US IVVD

1.1USD
-0.04(3.51%)

Last update at 2026-06-03T20:00:00Z

Day Range

1.091.14
LowHigh

52 Week Range

0.985.20
LowHigh

Fundamentals

  • Previous Close 1.14
  • Market Cap210.00M
  • Volume2826168
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-215.14600M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-1.71

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31
Income before tax -241.31700M -226.79000M -
Minority interest - - -
Net income -234.60300M -234.28900M -
Selling general administrative 47.04M 36.52M -
Selling and marketing expenses - - -
Gross profit - - -
Reconciled depreciation 0.46M 0.00100M -
Ebit -248.03100M -226.90800M -43.20344M
Ebitda -204.48500M -211.90800M -
Depreciation and amortization 43.55M 15.00M -
Non operating income net other 6.71M - -
Operating income -248.03100M -226.90800M -
Other operating expenses 226.26M 219.41M -
Interest expense 43.08M 15.00M -
Tax provision - - -
Interest income - - -
Net interest income - - -
Extraordinary items - - -
Non recurring 4.40M - -
Other items - - -
Income tax expense -6.71400M 7.50M -
Total revenue 0.00000M 0.00000M -
Total operating expenses 226.26M 219.41M -
Cost of revenue - - -
Total other income expense net 6.71M 0.12M -
Discontinued operations - - -
Net income from continuing ops -241.31700M -226.79000M -
Net income applicable to common shares -241.31700M -226.79000M -111.97545M
Preferred stock and other adjustments - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Total assets 229.18M 383.17M 620.09M 117.38M
Intangible assets - - - -
Earning assets - - - -
Other current assets 23.31M 4.93M 25.29M 0.14M
Total liab 51.71M 27.20M 62.07M 182.63M
Total stockholder equity 177.47M 355.97M 558.02M -65.24900M
Deferred long term liab - - - -
Other current liab 40.90M 21.95M 56.28M 4.92M
Common stock 0.01M 0.01M 0.01M 0.00100M
Capital stock 0.01M 0.01M 0.01M 89.71M
Retained earnings -732.06900M -533.42600M -292.10900M -65.31900M
Other liab - 0.00100M 0.01M 0.01M
Good will - - - -
Other assets - 0.19M 3.30M -
Cash 200.64M 92.08M 542.22M 114.99M
Cash and equivalents - - - -
Total current liabilities 50.29M 25.03M 62.06M 13.07M
Current deferred revenue - - - -
Net debt -198.47600M -88.35200M -542.22400M -114.98800M
Short term debt 1.44M 1.56M - -
Short long term debt - - - -
Short long term debt total 2.17M 3.72M - -
Other stockholder equity 680.36M 506.49M 850.12M -89.63700M
Property plant equipment - 2.28M 0.08M -
Total current assets 224.88M 376.92M 616.71M 117.38M
Long term investments - - - -
Net tangible assets - 355.97M 558.02M -65.24900M
Short term investments 0.00000M 279.92M 49.19M -
Net receivables 0.93M 0.38M 0.23M -
Long term debt - - - -
Inventory - -0.37700M - -
Accounts payable 7.95M 1.52M 5.78M 8.15M
Total permanent equity - - - -
Noncontrolling interest in consolidated entity - - - -
Temporary equity redeemable noncontrolling interests - - - -
Accumulated other comprehensive income -0.01300M -0.27200M -0.00800M -
Additional paid in capital - - - -
Common stock total equity - 0.01M - -
Preferred stock total equity - - - -
Retained earnings total equity - -533.42600M - -
Treasury stock - - - -
Accumulated amortization - - - -
Non currrent assets other 0.17M 0.19M 3.30M -
Deferred long term asset charges - - - -
Non current assets total 4.30M 6.25M 3.38M 0.00000M
Capital lease obligations 2.17M 3.72M - -
Long term debt total - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31
Investments -228.96200M -50.62700M -50.62700M
Change to liabilities -39.12800M -2.37000M 13.98M
Total cashflows from investing activities -230.66700M -50.71100M -50.71100M
Net borrowings - - -
Total cash from financing activities 0.51M 662.68M 222.10M
Change to operating activities -11.83000M 25.16M 4.33M
Net income -241.31700M -226.79000M -111.97545M
Change in cash -450.14800M 427.24M 197.12M
Begin period cash flow 542.22M 114.99M -
End period cash flow 92.08M 542.22M 114.99M
Total cash from operating activities -219.98700M -184.73600M -24.97886M
Issuance of capital stock 0.00000M 666.07M -
Depreciation 0.46M 0.00100M 0.00100M
Other cashflows from investing activities - - -
Dividends paid - - -
Change to inventory - - -
Change to account receivables - - -
Sale purchase of stock -0.00400M 0.00000M -
Other cashflows from financing activities 0.27M 331.78M -3.38500M
Change to netincome 39.02M 19.26M 68.69M
Capital expenditures 1.71M 0.08M 0.08M
Change receivables - - -
Cash flows other operating 23.42M - -
Exchange rate changes - - -
Cash and cash equivalents changes -450.14800M - -
Change in working capital -16.13000M 22.79M -
Stock based compensation 21.65M 17.76M -
Other non cash items 15.35M 0.07M -
Free cash flow -221.69200M -184.82000M -

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to EBITDA (x)
IVVD
Invivyd Inc.		 -0.04 3.51% 1.10 - - - 1.98 -0.7447
NVO
Novo Nordisk A/S		 -0.92 2.14% 42.00 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -0.75 1.73% 42.50 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 3.25 0.76% 428.34 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 16.03 2.66% 618.95 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Invivyd, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19. The company also has discovery stage candidates for the prevention of seasonal influenza and COVID-19. It has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was formerly known as Adagio Therapeutics, Inc. and changed its name to Invivyd, Inc. in September 2022. Invivyd, Inc. was incorporated in 2020 and is headquartered in Waltham, Massachusetts.

Invivyd Inc.

1601 Trapelo Road, Waltham, MA, United States, 02451

Key Executives

Name Title Year Born
Mr. David Hering M.B.A. CEO & Director 1975
Ms. Jill Andersen J.D. Chief Legal Officer & Corp. Sec. 1973
Ms. Laura Walker Ph.D. Co-Founder & Chief Scientific Officer 1985
Mr. Frederick W. Driscoll Interim CFO, Principal Financial Officer & Principal Accounting Officer 1951
Dr. Rebecca Dabora Ph.D. Chief Technology & Manufacturing Officer 1959
Kyra Rosow Faircloth VP of Gov. Affairs, Advocacy & Corp. Communication NA
Dr. Peter C. Schmidt M.D., M.Sc. Chief Medical Officer NA
Mr. David Hering M.B.A. CEO & Director 1976
Ms. Jill Andersen J.D. Chief Legal Officer & Corporate Secretary 1973
Mr. William E. Duke Jr., M.B.A. Chief Financial Officer 1972

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions